论文部分内容阅读
目的:探讨以羟基喜树碱为主要抗癌药的三联配方,对中晚期肝癌施行介入灌注化疗加栓堵术的临床应用价值与疗效分析。方法:回顾性分析8年来资料较齐全的中晚期肝癌230例;所有患者均经过临床确诊后采用以羟基喜树碱为主的三联抗癌药进行了1次～6次不等的介入灌注栓堵术,总治疗次数532次。结果:单纯用药物灌注者68人次,占29%;灌注加碘化油及手术线段或明胶海绵栓堵者,162例,占71%。治疗后208例患者精神症状好转,食欲增加;128例术前腹痛的患者疼痛明显减轻或消失;152例患者术后体重增加。生存期超过6个月者达94%,超过2a者达27%,5例超过4a,最长1例患者生存期达到5年8个月。结论:以羟基喜树碱为主要抗癌药进行介入灌注化疗所出现的副反应较轻且易于恢复。针对肝癌细胞的增殖期和非增殖期,筛选特异性及非特异性抗癌药物配伍,对号称癌中之王的中晚期肝癌施行介入灌注化疗加栓堵术,疗效较好,副作用小。
OBJECTIVE: To investigate the clinical value and the curative effect of triple therapy with hydroxycamptothecin as the main anticancer drug in the treatment of advanced hepatocellular carcinoma by percutaneous chemoembolization. Methods: A retrospective analysis of 230 cases of advanced hepatocellular carcinoma with more complete data over the past 8 years; all patients were clinically diagnosed with hydroxycamptothecin-based triple anticancer drugs once to 6 times ranging from perfusion plug Block surgery, the total number of 532 treatment times. Results: Drug infusion alone 68 people, accounting for 29%; perfusion iodized oil and surgery line or gelatin sponge embolism, 162 cases, accounting for 71%. After treatment, 208 patients improved their mental symptoms and increased their appetite. Pain in 128 patients with preoperative abdominal pain was significantly reduced or disappeared; 152 patients gained weight after operation. Survival of more than 6 months up to 94%, over 2a up to 27%, 5 cases over 4a, up to 1 patient survival of 5 years and 8 months. CONCLUSIONS: The side effects of chemotherapeutic intervention with hydroxycamptothecin as the primary anti-cancer drug are mild and readily regained. Targeting the proliferative and non-proliferative phase of hepatocellular carcinoma cells, screening specific and non-specific anticancer drug compatibility, the treatment of advanced hepatocarcinoma, known as the king of cancer, with chemoembolization and chemoembolization has good curative effect and small side effects.